Latest news

• Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis

  Almirall has announced that its IL-13 inhibitor lebrikizumab has been recommended by the European Medicines Agency’s human medicines committee to treat moderate-to-severe atopic dermatitis.

• Almirall shares positive topline results from atopic dermatitis trials

  Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... Lebrikizumab is a novel, monoclonal antibody

• Lilly expands dermatology portfolio with $1.1bn Dermira deal

  The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a

• MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

  Atopic dermatitis was poorly-served with therapies for years, but latterly has seen new treatment options come to market including Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent ... There are a number of drugs coming through the collective

• FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

  Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic